Products for Research Use Only

Carvedilol-d5

CAT: 0804-HY-B0006S2-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0006S2-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Carvedilol-d5 is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
CAS Number
929106-58-1
Product Name Alternative
BM 14190-d5
UNSPSC
12352005
Hazard Statement
H401-H411
Target
Adrenergic Receptor; Autophagy; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; GPCR/G Protein; Neuronal Signaling; Others
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
COC(C=CC=C1)=C1OCCNC([2H])([2H])C(O)([2H])C([2H])([2H])OC2=C3C4=CC=CC=C4NC3=CC=C2
Molecular Formula
C24H21D5N2O4
Molecular Weight
411.51
Precautions
P273-P391-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27 (1) :19-22.|[3]Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11 (4) :S41-8.|[4]Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported